Influence of entry criteria on mortality risk and number of eligible patients in recent studies on severe sepsis

Critical Care Medicine

Volumn 33, Issue 10, 2005, Pages 2178-2183

  Peelen, Linda ^a   De Keizer, Nicolette F ^a   Peek, Niels ^a   Bosman, Robert J ^b   Scheffer, Gert Jan ^c   De Jonge, Evert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Case mix; Randomized controlled trials; Selection criteria; Sepsis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTITHROMBIN III; DROTRECOGIN; LENERCEPT; LEXIPAFANT; MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2 INHIBITOR; POLYMYXIN B; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; VARESPLADIB;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CASE MIX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MEDLINE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK; SEPSIS;

EID: 26444594246     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000181733.16353.2C     Document Type: Article

References (23)

1. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
2. Levy MM, Fink MP, Marshall JC, et al: for the International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-538
3. Arts DGT, De Keizer NF, Scheffer GJ: Defining and improving data quality in medical registries: A literature review, case study, and generic framework. J Am Med Inform Assoc 2002; 9:600-611
4. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
5. Cole L, Bellomo R, Hart G, et al: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30:100-106
6. Reinhart K, Menges T, Gardlund B, et al: Randomized placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-769
7. Abraham E, Reinhart K, Svoboda P, et al: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind dose escalation study. Crit Care Med 2001; 29:2081-2089
8. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
9. Abraham E, Laterre PF, Garbino J, et al: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-510
10. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
11. 2, in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31:718-728
12. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient: High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
13. Angus DC, Birmingham MC, Balk RA, et al: Caring for the critically ill patient: E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: A randomized controlled trial. JAMA 2000; 283:1723-1730
14. Schuster DP, Metzler M, Opal S, et al: Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase lib, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31:1612-1619
15. Suputtamongkol Y, Intaranongpai S, Schmidt MD, et al: A double-blind placebo-controlled study of an infusion of Lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrobial Agents Chemother 2000; 44:693-696
16. Nemoto H, Nakamoto H, Okada H, et al: Newly developed immobilized Polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 2001; 19:361-369
17. Knaus WA, Draper EA, Wagner DP et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
18. Maccioli GA: Sepsis and trials: Are we studying the right patients in the correct fashion? Crit Care Med 2002; 30:2594-2595
19. Krueger WA, Unertl KE: Selective decontamination of the digestive tract. Curr Opin Crit Care 2002; 8:139-144
20. Ely EW, Laterre PF, Angus DC, et al: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
21. Warren HS, Suffredini AS, Eichacker PQ et al: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1029
22. Sun X, Wagner DP, Knaus WA: Does selective decontamination of the digestive tract reduce mortality for severely ill patients? Crit Care Med 1996; 24:753-755
23. Marshall JC: Clinical trials of mediator-directed therapy in sepsis: What have we learned? Intensive Care Med 2000; 26: S75-S83